M&As this week: RTI Surgical, Illumina, ResMed

9 November 2018 (Last Updated November 9th, 2018 11:01)

RTI Surgical has signed an agreement to acquire Paradigm Spine in a cash and stock deal valued up to $300m.

RTI Surgical has signed an agreement to acquire Paradigm Spine in a cash and stock deal valued up to $300m.

Paradigm Spine will receive $100m in cash and 10.7 million shares of RTI Surgical’s common stock worth approximately $50m. The company will also receive milestone payments in cash and RTI common stock.

The acquisition will reduce RTI’s complexity and improve its operational efficiency and growth. It will provide the company with access to Paradigm’s Interlaminar Stabilization device Coflex®, which is available in more than 40 countries. The device is intended to improve the company’s spinal management solution offerings and strengthen its customer base.

Both parties involved in the transaction are medical technology companies based in the US.

Illumina has agreed to purchase Pacific Biosciences in an all-cash transaction worth approximately $1.2bn.

The acquisition will expand Pacific Biosciences’ offerings by integrating its long-read sequencing capabilities with Illumina’s existing short-read gene sequencing platforms.

"The device is intended to improve the company’s spinal management solution offerings and strengthen its customer base."

Illumina will be able to provide integrated workflows and novel solutions on the basis of both the technologies, which will enable in developing cost-effective tests. The integration of the technologies will also improve the speed of genomic discovery.

The deal is expected to close by mid-2019, subject to customary closing conditions and approvals.

Both companies involved in the transaction are biotechnology companies based in the US.

ResMed has agreed to purchase MatrixCare for $750m, which is expected to improve the former’s software-as-a-service (SaaS) offerings.  which are provided through Brightree and HEALTHCAREfirst across the areas of home medical equipment, home health, and hospices.

MatrixCare’s main product is its electronic health record (EHR) solution, which enhances patient management ability and clinical care.

The acquisition is expected to close by the second quarter of 2019, subject to customary closing conditions and regulatory approvals.

MatrixCare will operate as a standalone company in ResMed’s SaaS portfolio, upon completion of the acquisition.

Both companies are based in the US and are involved in medical equipment.